Neuroprotection and its molecular mechanism following spinal cord injury

Neural Regeneration Research

Volumn 7, Issue 26, 2012, Pages 2051-2062

  Liu, Nai Kui ^a   Xu, Xiao Ming ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Glucocorticoid receptor; Inflammation; MicroRNAs; Neuroprotection; Oxidation; Phospolipase A2; Signaling pathway; Spinal cord injury

Indexed keywords

EID: 84892679943     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2012.26.007     Document Type: Article

References (99)

1. [1] Olivas AD, Noble-Haeusslein LJ. Phospholipase A2 and spinal cord injury: a novel target for therapeutic intervention. Ann Neurol. 2006;59:577-579.
2. [2] Park E, Velumian AA, Fehlings MG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma. 2004;21: 754-774.
3. [3] Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx. 2004;1:80-100.
4. [4] Carlson SL, Parrish ME, Springer JE, et al. Acute inflammatory response in spinal cord following impact injury. Exp Neurol. 1998;151:77-88.
5. [5] Mautes AE, Weinzierl MR, Donovan F, et al. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther. 2000;80:673-687.
6. [6] Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997;377:443-464.
7. [7] Resnick DK, Nguyen P, Cechvala CF. Regional and temporal changes in prostaglandin E2 and thromboxane B2 concentrations after spinal cord injury. Spine J. 2001;1:432-436.
8. [8] Streit WJ, Semple-Rowland SL, Hurley SD, et al. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol. 1998;152:74-87.
9. [9] Tonai T, Taketani Y, Ueda N, et al. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats. J Neurochem. 1999;72:302-309.
10. [10] Wang CX, Olschowka JA, Wrathall JR. Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res. 1997;759:190-196.
11. [11] Xu J, Fan G, Chen S, et al. Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res Mol Brain Res. 1998;59: 135-142.
12. [12] Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci. 1994;6:712-724.
13. [13] Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
14. [14] Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240-246.
15. [15] Xu J, Kim GM, Ahmed SH, et al. Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci. 2001;21:92-97.
16. [16] Bethea JR, Castro M, Keane RW, et al. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci. 1998;18:3251-3260.
17. [17] Chiu R, Boyle WJ, Meek J, et al. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 1988;54:541-552.
18. [18] Halazonetis TD, Georgopoulos K, Greenberg ME, et al. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 1988;55:917-924.
19. [19] Gasparini C, Feldmann M. NF-kappaB as a target for modulating inflammatory responses. Curr Pharm Des. 2012.
20. [20] Bond M, Baker AH, Newby AC. Nuclear factor kappa B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun. 1999;264:561-567.
21. [21] Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1betastimulated synovial fibroblasts. Arthritis Rheum. 1998;41:1987-1994.
22. [22] Yokoo T, Kitamura M. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol. 1996;270:F123-130.
23. [23] Bond M, Fabunmi RP, Baker AH, et al. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998;435: 29-34.
24. [24] Yong VW, Krekoski CA, Forsyth PA, et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998;21:75-80.
25. [25] Hsu CY, Hogan EL, Gadsden RH Sr, et al. Vascular permeability in experimental spinal cord injury. J Neurol Sci. 1985;70:275-282.
26. [26] Smith JA, Das A, Ray SK, et al. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87:10-20.
27. [27] Yakovlev AG, Faden AI. Sequential expression of c-fos protooncogene, TNF-alpha, and dynorphin genes in spinal cord following experimental traumatic injury. Mol Chem Neuropathol. 1994;23:179-190.
28. [28] Wang CX, Nuttin B, Heremans H, et al. Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J Neuroimmunol. 1996;69:151-156.
29. [29] Bartholdi D, Schwab ME. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci. 1997;9:1422-1438.
30. [30] Yan P, Li Q, Kim GM, et al. Cellular localization of tumor necrosis factor-alpha following acute spinal cord injury in adult rats. J Neurotrauma. 2001;18:563-568.
31. [31] Yan P, Liu N, Kim GM, et al. Expression of the type 1 and type 2 receptors for tumor necrosis factor after traumatic spinal cord injury in adult rats. Exp Neurol. 2003;183: 286-297.
32. [32] Kim GM, Xu J, Song SK, et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci. 2001;21:6617-6625.
33. [33] Constantini S, Young W. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg. 1994;80:97-111.
34. [34] Moalem G, Leibowitz-Amit R, Yoles E, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5:49-55.
35. [35] Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998;4:814-821.
36. [36] Nawashiro H, Tasaki K, Ruetzler CA, et al. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 1997;17:483-490.
37. [37] Gary DS, Bruce-Keller AJ, Kindy MS, et al. Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab. 1998;18:1283-1287.
38. [38] Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2: 788-794.
39. [39] Yan P, Xu J, Li Q, et al. Glucocorticoid receptor expression in the spinal cord after traumatic injury in adult rats. J Neurosci. 1999;19:9355-9363.
40. [40] Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
41. [41] Chen A, Xu XM, Kleitman N, et al. Methylprednisolone administration improves axonal regeneration into Schwann cell grafts in transected adult rat thoracic spinal cord. Exp Neurol. 1996;138:261-276.
42. [42] Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
43. [43] Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94:557-572.
44. [44] Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500:51-62.
45. [45] Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol. 2006;147 Suppl 1: S258-268.
46. [46] Fuxe K, Harfstrand A, Agnati LF, et al. Immunocytochemical studies on the localization of glucocorticoid receptor immunoreactive nerve cells in the lower brain stem and spinal cord of the male rat using a monoclonal antibody against rat liver glucocorticoid receptor. Neurosci Lett. 1985;60:1-6.
47. [47] Ahima RS, Harlan RE. Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience. 1990;39:579-604.
48. [48] Liu N, Han S, Lu PH, et al. Upregulation of annexins I, II, and V after traumatic spinal cord injury in adult rats. J Neurosci Res. 2004;77:391-401.
49. [49] Liu NK, Zhang YP, Han S, et al. Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. J Neuropathol Exp Neurol. 2007;66:932-943.
50. [50] Liu D, Liu J, Wen J. Elevation of hydrogen peroxide after spinal cord injury detected by using the Fenton reaction. Free Radic Biol Med. 1999;27:478-482.
51. [51] Liu D, Sybert TE, Qian H, et al. Superoxide production after spinal injury detected by microperfusion of cytochrome c. Free Radic Biol Med. 1998;25:298-304.
52. [52] Liu D, Liu J, Sun D, et al. The time course of hydroxyl radical formation following spinal cord injury: the possible role of the iron-catalyzed Haber-Weiss reaction. J Neurotrauma. 2004;21:805-816.
53. [53] Scott GS, Cuzzocrea S, Genovese T, et al. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A. 2005;102:3483-3488.
54. [54] Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993;16:439-444.
55. [55] Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-1437.
56. [56] Xu J, Kim GM, Chen S, et al. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma. 2001; 18:523-532.
57. [57] Sharma HS, Westman J, Olsson Y, et al. Involvement of nitric oxide in acute spinal cord injury: an immunocytochemical study using light and electron microscopy in the rat. Neurosci Res. 1996;24:373-384.
58. [58] Farooque M, Isaksson J, Olsson Y. Improved recovery after spinal cord injury in neuronal nitric oxide synthase-deficient mice but not in TNF-alpha-deficient mice. J Neurotrauma. 2001;18:105-114.
59. [59] Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci. 1997;17: 5395-5406.
60. [60] Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3:73-76.
61. [61] Liu NK, Xu XM.: Phospholipase A2 and its molecular mechanism after spinal cord injury. Mol Neurobiol. 2010;41:197-205.
62. [62] Liu NK, Titsworth WL, Xu XM. Phospholipase A2 in CNS disorders: Implication on traumatic spinal cord and brain injuries. In: Banik N, Ray SK, eds. Handbook of Neurochemistry and Molecular Neurobiology: Brain and Spinal Cord Trauma. 3rd ed. New York: Springer. 2009:321-341.
63. [63] Titsworth WL, Liu NK, Xu XM. Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury. CNS Neurol Disord Drug Targets. 2008;7:254-269.
64. [64] Liu NK, Zhang YP, Titsworth WL, et al. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol. 2006;59:606-619.
65. [65] Titsworth WL, Cheng X, Ke Y, et al. Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death. Glia. 2009;57:1521-1537.
66. [66] Liu NK, Titsworth WL, Zhang YP, et al. Characterizing phospholipase A2-induced spinal cord injury—A comparison with contusive spinal cord injury in adult rats. Transl Stroke Res. 2011;2:608-618.
67. [67] Titsworth WL, Onifer SM, Liu NK, et al. Focal phospholipases A2 group III injections induce cervical white matter injury and functional deficits with delayed recovery concomitant with Schwann cell remyelination. Exp Neurol. 2007;207:150-162.
68. [68] Zhao Z, Liu N, Huang J, et al. Inhibition of cPLA2 activation by Ginkgo biloba extract protects spinal cord neurons from glutamate excitotoxicity and oxidative stress-induced cell death. J Neurochem. 2011;116: 1057-1065.
69. [69] Park KK, Liu K, Hu Y, et al. PTEN/mTOR and axon regeneration. Exp Neurol. 2010;223:45-50.
70. [70] Park KK, Liu K, Hu Y, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science. 2008;322:963-966.
71. [71] Song W, Volosin M, Cragnolini AB, et al. ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J Neurosci. 2010;30: 15608-15615.
72. [72] Zhang QG, Wu DN, Han D, et al. Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury. FEBS Lett. 2007;581:495-505.
73. [73] Sury MD, Vorlet-Fawer L, Agarinis C, et al. Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis. Neurobiol Dis. 2011;41:201-208.
74. [74] Walker CL, Walker MJ, Liu NK, et al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS One. 2012;7:e30012.
75. [75] Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 1996;85:1113-1124.
76. [76] Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature. 1996;382:80-83.
77. [77] Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 1996;381:785-789.
78. [78] Trupp M, Raynoschek C, Belluardo N, et al. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase. Mol Cell Neurosci. 1998;11:47-63.
79. [79] Iannotti C, Ping Zhang Y, Shields CB, et al. A neuroprotective role of glial cell line-derived neurotrophic factor following moderate spinal cord contusion injury. Exp Neurol. 2004;189:317-332.
80. [80] Cheng H, Wu JP, Tzeng SF. Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury. J Neurosci Res. 2002;69: 397-405.
81. [81] Fargo KN, Foecking EM, Jones KJ, et al. Neuroprotective actions of androgens on motoneurons. Front Neuroendocrinol. 2009;30:130-141.
82. [82] Fargo KN, Sengelaub DR. Testosterone manipulation protects motoneurons from dendritic atrophy after contralateral motoneuron depletion. J Comp Neurol. 2004;469:96-106.
83. [83] Fargo KN, Sengelaub DR. Exogenous testosterone prevents motoneuron atrophy induced by contralateral motoneuron depletion. J Neurobiol. 2004;60:348-359.
84. [84] Jones KJ, Durica TE, Jacob SK. Gonadal steroid preservation of central synaptic input to hamster facial motoneurons following peripheral axotomy. J Neurocytol. 1997;26:257-266.
85. [85] Clark MJ, Petroski GF, Mazurek MO, et al. Testosterone replacement therapy and motor function in men with spinal cord injury: a retrospective analysis. Am J Phys Med Rehabil. 2008;87:281-284.
86. [86] Byers JS, Huguenard AL, Kuruppu D, et al. Neuroprotective effects of testosterone on motoneuron and muscle morphology following spinal cord injury. J Comp Neurol. 2012;520:2683-2696.
87. [87] Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics. 2011;43:571-580.
88. [88] Krichevsky AM. MicroRNA profiling: from dark matter to white matter, or identifying new players in neurobiology. ScientificWorldJournal. 2007;7:155-166.
89. [89] Bak M, Silahtaroglu A, Moller M, et al. MicroRNA expression in the adult mouse central nervous system. RNA. 2008;14:432-444.
90. [90] Kosik KS. The neuronal microRNA system. Nat Rev Neurosci. 2006;7:911-920.
91. [91] Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5:R68.
92. [92] Liu NK, Wang XF, Lu QB, et al. Altered microRNA expression following traumatic spinal cord injury. Exp Neurol. 2009;219:424-429.
93. [93] Strickland ER, Hook MA, Balaraman S, et al. MicroRNA dysregulation following spinal cord contusion: implications for neural plasticity and repair. Neuroscience. 2011;186: 146-160.
94. [94] Yunta M, Nieto-Diaz M, Esteban FJ, et al. MicroRNA dysregulation in the spinal cord following traumatic injury. PLoS One. 2012;7:e34534.
95. [95] Esau CC, Monia BP. Therapeutic potential for microRNAs. Adv Drug Deliv Rev. 2007;59:101-114.
96. [96] Mirnezami AH, Pickard K, Zhang L, et al. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol. 2009;35:339-347.
97. [97] Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 2006;13:496-502.
98. [98] Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-658.
99. [99] Medina PP, Slack FJ. Inhibiting microRNA function in vivo. Nat Methods. 2009;6:37-38.